NCT05489237 2025-11-17First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsIDRx Inc. - A GSK CompanyPhase 1 Recruiting278 enrolled
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled